A) HepG2 cells were treated with MAT1A OV or si, or FOXM1 OV or si, and respective controls for 24 hours. ChIP analysis with anti-FOXM1 or MATα1 antibody, and then re-ChIP with anti-MATα1, p65, p50 antibodies after FOXM1 ChIP were performed as described in Materials and Methods. Representative results from three experiments are shown. B) Activities of the wild-type (WT) and FOX binding site mutants (MU) of the FOXM1 promoter after MAT1A OV and si treatment for 24 hours in HepG2 cell. Results are expressed as mean % of EV or SC ± SEM from three experiments done in duplicates *p < 0.05 vs. EV or. SC. C) Promoter activities of the WT and FOX binding site MU of the FOXM1 promoter after p65 OV for 24 hours in the HepG2 cell. Results are expressed as mean % of EV ± SEM from three experiments done in duplicates. *p < 0.05 vs. EV. Results represent at least three independent experiments done in duplicate.